By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on Biotechnology. According to news originating from Galway, Ireland, by NewsRx correspondents, research stated, "Cornea transplantation (penetrating keratoplasty) is the most frequently performed transplant procedure in humans. Despite advances in microsurgery and immunosuppressive treatment protocols, a significant number of corneal grafts still undergo immune-mediated allograft rejection."
Our news journalists obtained a quote from the research from National University, "Topical treatment with corticosteroids is currently the gold standard and while this treatment is effective in many corneal transplant patients, it is much less effective in 'high-risk' patients with previous episodes of neovascularisation or graft rejection. Therefore, alternative approaches such as genetic modification of donor corneas are needed to prevent corneal transplant rejection. Cornea transplantation holds the unique advantage in that gene therapy can be used to modify allografts ex vivo prior to transplantation. Many preclinical studies using local (and systemic) gene transfer have been performed to date and many different gene transfer vehicles (gene therapy vectors) and therapeutic strategies (immunomodulatory or graft-protective) have been investigated to prevent corneal allograft rejection.The most recent gene therapy applications to prevent corneal allograft rejection will be reviewed in this article."
According to the news editors, the research concluded: "Moreover, it will be discussed why the development of clinical trials for the genetic modification of corneal grafts prior to transplantation is lagging behind of those for the treatment of inherited retinal diseases."
For more information on this research see: Gene Therapy Approaches to Prevent Corneal Graft Rejection: Where Do We Stand? Ophthalmic Research, 2013;50(3):135-140. Ophthalmic Research can be contacted at: Karger, Allschwilerstrasse 10, Ch-4009 Basel, Switzerland. (Karger - www.karger.com/; Ophthalmic Research - content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=223858)
The news correspondents report that additional information may be obtained from T. Ritter, Natl Univ Ireland, Sch Med, Regenerat Med Inst, Coll Med Nursing & Hlth Sci, Galway, Ireland. Additional authors for this research include M. Wilk and M. Nosov (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Galway, Europe, Ireland, Genetics, Treatment, Gene Therapy, Therapeutics, Bioengineering, Pre-Trial Research, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC